These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29588724)

  • 1. PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent.
    Byrne RA; Eeckhout E; Sardella G; Stella P; Verheye S
    Interv Cardiol; 2017 May; 12(1):13-17. PubMed ID: 29588724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in Patients with Diabetes: Improving Clinical Outcomes After Percutaneous Coronary Intervention Through EVOlving Stent Technology.
    Byrne RA; Banai S; Colleran R; Colombo A
    Interv Cardiol; 2018 Jan; 13(1):40-44. PubMed ID: 29593836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meeting the Unmet - The Cre8 Polymer-free Drug-eluting Stents Technology: Proceedings of a satellite symposium held at EuroPCR on May 20th - 23rd 2014 in Paris.
    Mountfort K; Carrié D; Valgimigli M; Sardella G; Banai S; Romaguera R; Stella P
    Interv Cardiol; 2014 Aug; 9(3):184-189. PubMed ID: 29588800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cre8™ coronary stent: preclinical in vivo assessment of a new generation polymer-free DES with Amphilimus™ formulation.
    Moretti C; Lolli V; Perona G; Vignolini MC; Cabiale K; Falzone M; Galloni M
    EuroIntervention; 2012 Jan; 7(9):1087-94. PubMed ID: 22130128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of the Cre8 Stent in Patients With Diabetes Mellitus.
    Carrié D
    Interv Cardiol; 2016 May; 11(1):47-50. PubMed ID: 29588705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cre8 amphilimus-eluting stent for the treatment of coronary artery disease: safety and efficacy profile.
    Pivato CA; Leone PP; Petriello G; Sanz-Sanchez J; Chiarito M; Stefanini GG
    Expert Rev Med Devices; 2020 Apr; 17(4):267-275. PubMed ID: 32151183
    [No Abstract]   [Full Text] [Related]  

  • 7. Polymer-free drug-eluting stent in unselected patient population: a single center experience.
    Konigstein M; Banai S; Herz I; Bazan S; Revivo M; Halkin A; Keren G; Finkelstein A; Arbel Y
    Cardiovasc Revasc Med; 2014; 15(6-7):350-3. PubMed ID: 25262477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-tailored Drug-eluting Stent Choice - A Solution for Patients with Diabetes: Proceedings of Two Satellite Symposia Held at EuroPCR in May 2015 in Paris.
    Mountfort K; Mehran R; Colombo A; Stella P; Romaguera R; Sardella G
    Interv Cardiol; 2015 Sep; 10(3):158-161. PubMed ID: 29588695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymer-free amphilimus-eluting stents in patients with diabetes mellitus.
    Romaguera R; Gómez-Lara J; Jacobi F; Gomez-Hospital JA; Cequier A
    Minerva Cardioangiol; 2014 Oct; 62(5):421-6. PubMed ID: 25295493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances with polymer-free amphilimus-eluting stents.
    CARRIé D
    Minerva Cardioangiol; 2016 Jun; 64(3):339-53. PubMed ID: 26934663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cre8™ Unique Technology in Challenging Daily Practice: Proceedings of a satellite symposium held at EuroPCR on 20th - 23rd May 2014 in Paris.
    Mountfort K; Antoniucci D; Mehran R; DeLuca G; Nef H; Vrolix M; Khashaba A
    Interv Cardiol; 2014 Aug; 9(3):180-183. PubMed ID: 29588799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year clinical outcome of amphilimus polymer-free drug-eluting stent in diabetes mellitus patients: Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTre rEgistry).
    Colombo A; Godino C; Donahue M; Testa L; Chiarito M; Pavon AG; Colantonio R; Cappelletti A; Monello A; Magni V; Milazzo D; Parisi R; Nicolino A; Moshiri S; Fattori R; Aprigliano G; Palloshi A; Caramanno G; Montorfano M; Bedogni F; Margonato A; Briguori C
    Int J Cardiol; 2016 Jul; 214():113-20. PubMed ID: 27060269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Contemporary Drug-Eluting Stents in Patients With Diabetes Mellitus.
    Yang Y; Hyun J; Lee J; Kim JH; Lee JB; Kang DY; Lee PH; Ahn JM; Park DW; Park SJ;
    JACC Asia; 2021 Sep; 1(2):173-184. PubMed ID: 36338165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year clinical outcome of multicenter randomized trial comparing amphilimus - with paclitaxel-eluting stents in de novo native coronary artery lesions.
    Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Musto C; Berti S; Dibié A; Maupas E; Antoniucci D; Schofer J
    Int J Cardiol; 2020 Feb; 301():50-55. PubMed ID: 31759686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents.
    Panoulas VF; Latib A; Naim C; Sato K; Ielasi A; Tespili M; Godino C; Testa L; Bedogni F; Colombo A
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1168-76. PubMed ID: 26269415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and study design of the RESERVOIR trial: a randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus.
    Romaguera R; Brugaletta S; Gomez-Lara J; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Gómez-Hospital JA; Montanya E; Alfonso F; Valgimigli M; Sabate M; Cequier A
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):E116-22. PubMed ID: 25380051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of Left Ventricular Systolic Function after Percutaneous Coronary Intervention in Diabetic Patients with Non-ST elevated Myocardial Infarction.
    Chowdhury MT; Hoque H; Mahmood M; Khaled FI; Iqbal KM; Mostafa Z; Shakil SS; Zaman SM
    Mymensingh Med J; 2020 Apr; 29(2):384-391. PubMed ID: 32506094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodegradable polymer-coated thin strut sirolimus- -eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population.
    Gasior P; Gierlotka M; Szczurek-Katanski K; Osuch M; Roleder M; Hawranek M; Wojakowski W; Polonski L
    Cardiol J; 2021; 28(2):235-243. PubMed ID: 31909473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions.
    Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Violini R; Dibie A; Berti S; Maupas E; Antoniucci D; Schofer J
    J Am Coll Cardiol; 2012 Apr; 59(15):1371-6. PubMed ID: 22284328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial.
    Konigstein M; Ben-Yehuda O; Smits PC; Love MP; Banai S; Perlman GY; Golomb M; Ozan MO; Liu M; Leon MB; Stone GW; Kandzari DE
    JACC Cardiovasc Interv; 2018 Dec; 11(24):2467-2476. PubMed ID: 30573057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.